Insurmountable angiotensin AT1 receptor antagonists: The role of tight antagonist binding

European Journal of Pharmacology

Volumn 372, Issue 2, 1999, Pages 199-206

  Fierens, Frederik L P ^a   Vanderheyden, Patrick M L ^a   De Backer, Jean Paul ^a   Vauquelin, Georges ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Angiotensin AT1 receptor; Angiotensin II; Antagonist; CHO (Chinese hamster ovary) cell; Inositol phosphate; Insurmountable; Surmountable

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; INOSITOL PHOSPHATE; IRBESARTAN; LOSARTAN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; IMIDAZOLE DERIVATIVE; RECOMBINANT PROTEIN; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BINDING COMPETITION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HAMSTER; HUMAN; METABOLISM;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BINDING, COMPETITIVE; BIPHENYL COMPOUNDS; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; LOSARTAN; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RECOMBINANT PROTEINS; TETRAZOLES;

EID: 0032587233     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00205-8     Document Type: Article

References (40)

1. Arunlakshana O., Schild H.O. Some quantitative use of drugs antagonists. Br. J. Pharmacol. 14:1959;48-52.
2. Balmforth A.J., Lee A.L., Warburton P., Donnelly D., Ball S.G. The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J. Biol. Chem. 272:1997;4245-4251.
3. 1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 265:1993;826-834.
4. Cirillo R., Renzetti A.R., Cucchi P., Guelfi M., Salimbeni A., Caliari S., Castellucci A., Evangelista S., Subissi A., Giachetti A. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin AT1 receptor antagonist. Br. J. Pharmacol. 114:1995;1117-1124.
5. Conchon S., Monnot C., Teutsch B., Corvol P., Clauser E. Internalization of the rat AT1a and AT1b receptors: pharmacological and functional requirements. FEBS Lett. 349:1994;365-370.
6. Convents A., De Backer J.-P., Vauquelin G. Tight agonist binding may prevent the correct interpretation of agonist competition binding curves of a2-adrenergic receptors. Mol. Pharmacol. 32:1987;65-72.
7. Crozat A., Penhoat A., Saez J.M. Processing of angiotensin II (A-II) and (sar1,Ala8)A-II by cultured bovine adrenocortical cells. Endocrinology. 118:1986;2312-2318.
8. Cvejic S., Devi L.A. Dimerization of the δ opioid receptor. J. Biol. Chem. 272:1997;26959-26964.
9. De Chaffoy de Courcelles D., Leysen J.E., Roevens P., Van Belle H. The serotonin-S2 receptor: a receptor, transducer coupling model to explain insurmountable antagonist effects. Drug Dev. Res. 8:1986;173-178.
10. De Lean A., Stadel J.M., Lefkowitz R.J. A ternary complex model explains the agonist-specific properties of the adenylate cyclase-coupled b adrenergic receptor. J. Biol. Chem. 255:1980;7108-7117.
11. Dickinson K.E., Cohen R.B., Skwish S., Delaney C.L., Serafino R.P., Poss M.A., Gu Z., Ryono D.E., Moreland S., Powell J.R. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br. J. Pharmacol. 113:1994;179-189.
12. 3H ]candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells Eur. J. Pharmacol. 367:1999;413-422.
13. Gero A. Desensitization, two-state receptors and pharmacological parameters. J. Theor. Biol. 103:1983;137-161.
14. Hara M., Kiyama R., Nakajima S., Kawabata T., Kawakami M., Ohtani K., Itazaki K., Fujishita T., Fujimoto M. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Eur. J. Pharmacol. 289:1995;267-273.
15. Hara et al., 1996.
16. Kenakin, T.P., 1987. Drug antagonism. In: Kenakin, T.P. (Ed.), Pharmacological Analysis of Drug-Receptor Interaction. Raven Press, New York, pp. 1-30 and 205-244.
17. Leff P. The two-state model of receptor activation. Trends Pharmacol. Sci. 16:1995;89-97.
18. Liu Y.J., Shankley N.P., Welsh N.J., Black J.W. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and synoptic action. Br. J. Pharmacol. 106:1992;233-241.
19. Mochizuki S., Sato T., Furata K., Hase K., Ohkura Y., Fukai C., Kosakai K., Wakabayashi S., Tomiyama A. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J. Cardiovasc. Pharmacol. 25:1995;22-29.
20. Monnot C., Bihoreau C., Conchon S., Curnow K.M., Corvol P., Clauser E. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. J. Biol. Chem. 271:1995;1507-1513.
21. Noda M., Shibouta Y., Inada Y., Ojima M., Wada T., Sanada T., Kubo K., Kohara Y., Naka T., Nishikawa K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist. Biochem. Pharmacol. 46:1993;311-318.
22. 1 receptor. Eur. J. Pharmacol. 319:1997;137-146.
23. Olins G.M., Chen S.T., McMahon E.G., Palomo M.A., Reitz D.B. Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629. Mol. Pharmacol. 47:1994;115-120.
24. 1 antagonism. J. Pharmacol. Exp. Ther. 273:1995;753-761.
25. Paton, W.D.M., Rang, H.P., 1966. The kinetic approach to drug antagonism. In: Harper, N.J., Simmonds, A.B. (Eds.), Advances in Drug Research, Vol. 3. Academic Press, New York, pp. 57-80.
26. Pendleton R.G., Gessner G., Horner E. Studies on inhibition of angiotensin II receptors in rabbit adrenal and aorta. J. Pharmacol. Exp. Ther. 248:1989;637-643.
27. Perlman S., Schambye H.T., Rivero R.A., Greenlee W.J., Hjorth S.A., Schwartz T.W. Non-peptide angiotensin agonist: functional and molecular interaction with the AT1 receptor. J. Biol. Chem. 270:1995;1493-1496.
28. Rang H.P. The kinetics of action of acetylcholine antagonist in smooth muscle. Proc. R. Soc. London (Biol.). 164:1966;488-510.
29. 1 receptor antagonist. Eur. J. Pharmacol. 290:1995;151-156.
30. Robertson M.J., Barnes J.C., Drew G.M., Clark K.L., Marshall F.H., Michel A., Middlemiss D., Ross B.C., Scopes D., Dowle M.D. Pharmacological profile of GR 117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br. J. Pharmacol. 107:1992;1173-1180.
31. Robertson M.J., Dougall I.G., Harper D., Mckechnie K.C.W., Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol. Sci. 15:1994;364-369.
32. Seeuwen K., Lagarde A., Pouysségur J. Deregulation of hamster fibroblast proliferation by mutated ras oncogenes is not mediated by constitutive activation of phosphoinositide-specific phospholipase C. EMBO J. 7:1988;161-168.
33. Severne Y., Ijzerman A., Nerme V., Zimmerman H., Vauquelin G. Shallow agonist competition binding curves for b-adrenergic receptors: the role for tight agonist binding. Mol. Pharmacol. 31:1986;69-73.
34. Shibouta Y., Inada Y., Ojima M., Wada T., Noda M., Sanada T., Kubo K., Kohara Y., Naka T., Nishikawa K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-l-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biohenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J. Pharmacol. Exp. Ther. 266:1993;114-120.
35. Timmermans P.B.M.W.M., Wong P.C., Chiu A.T., Herblin W.F. Nonpeptide angiotensin I receptor antagonists. Trends. Pharmacol. Sci. 12:1991;55-62.
36. Timmermans P.B.M.W.M., Benfield P., Chiu A.T., Herblin W.F., Wong P.C. Angiotensin II receptors and functional correlates. Am. J. Hypertens. 5:1992;221S-235S.
37. Vallotton M.B. The renin-angiotensin system. Trends. Pharmacol. Sci. 8:1987;69-74.
38. 1 receptors. Br. J. Pharmacol. 126:1999;1057-1065.
39. Wienen W., Hauel N., Van Meel J.C.A., Narr B., Ries U., Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110:1993;245-252.
40. Wong P.C., Price A.W., Chiu A.T., Duncia J.V., Carini D.J., Wexler R., Johnson A., Timmermans P.B.M.W.M. Nonpeptide angiotensin receptor antagonists: XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 255:1990;211-217.